| Name | Title | Contact Details |
|---|
You can count on Rushlight Ventures to maximize the value of your intellectual property (IP). Rushlight Ventures is a leading venture studio that specializes in the monetization of defense and dual-use intellectual property created by small and mid-sized businesses conducting federally sponsored research. We are both "IP type" and "monetization path" agnostic. We can pursue value creation from your IP via licenses, asset sales, startups, joint ventures, M&A, or internal business units. We work with IP of all varieties, including products, patents, trade secrets, proprietary relationships, and know-how. At Rushlight Ventures, we provide a range of consulting and support services, including: • Licensing • Asset sales • Joint ventures • Startup and spin-out creation • Commercialization planning and TABA support Companies primarily focused on delivering high-quality research, development, testing, and evaluation services (RDT&E) and other large programs may find it challenging to be equally adept at technology commercialization. Thats why Rushlight Ventures (RLV) originated as a venture studio in 2020 within Cornerstone Research Group (CRG), its sister company and a renowned government contractor for more than 25 years. Soon after forming the venture studio, leadership realized that CRG was not the only company grappling with transition and monetization difficulties, and RLV was spun off as an independent entity in 2021. Today, RLV successfully bridges the gap between RDT&E and commercialization through its seasoned team. RLV staff possess decades of experience in new technology development and commercialization, aerospace and defense RDT&E, new company formation, financing, licensing, and mergers and acquisitions. We have the knowledge and ability to take you from now to wow.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.
The Faulkner Organization is a family-owned automotive dealership group based in Pennsylvania, founded in 1932. With a legacy of over nine decades, it operates 31 dealerships across Central and Southeastern Pennsylvania, representing 22 vehicle brands. The company specializes in the sale and service of new and pre-owned vehicles. Their offerings include automotive sales, maintenance and repair services, financing and insurance assistance, genuine parts supply, and body shop repair services. The Faulkner Organization is committed to customer satisfaction, employee development, and maintaining high ethical standards in all business dealings.
The IRONMAN Group is a leading organization in endurance sports, hosting over 230 events annually in more than 55 countries. Founded in 1978 with the first Hawaiian Iron Man Triathlon, the company has evolved from a single race into a global phenomenon, attracting over 600,000 participants each year. It operates as the largest mass-participation sports organizer worldwide, originally established as the World Triathlon Corporation in 1991. The IRONMAN Group offers a diverse portfolio of events, including the full-distance IRONMAN® Triathlon, the half-distance IRONMAN® 70.3®, and the Olympic-distance 5150™ Triathlon Series. They also organize running events like the Rock ‘n’ Roll® Running Series and the Standard Chartered Singapore Marathon™, as well as trail running and cycling events. The company promotes inclusivity, catering to elite athletes, amateur enthusiasts, families, and youth through programs like IRONKIDS® and Iron Girl®. Their mission is to inspire athletes of all levels with the ethos "ANYTHING IS POSSIBLE®."